Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Glass

Showing results (611-620 of 667) with videos related to

Pageof 67
Sort By:
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 9, 2008
50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosisWendy J Broom, Matthew Greenway, Ghazaleh Sadri-Vakili, et al.
Neurology|October 27, 2004
Clinical and neuropathologic variation in neuronal intermediate filament inclusion diseaseN J Cairns, M Grossman, S E Arnold, et al.
The New England Journal of Medicine|September 21, 2022
Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy M Miller, Merit E Cudkowicz, Angela Genge, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Nature Neuroscience|January 10, 2018
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTDChing-Chieh Chou, Yi Zhang, Mfon E Umoh, et al.
Neurobiology of Aging|April 23, 2010
Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosisElke Bogaert, An Goris, Philip Van Damme, et al.
Molecular Neurodegeneration|May 15, 2025
Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisAdam N Trautwig, Edward J Fox, Eric B Dammer, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Pageof 67

Showing results (611-620 of 667) with videos related to

Sort By:
Pageof 67
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 9, 2008
50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosisWendy J Broom, Matthew Greenway, Ghazaleh Sadri-Vakili, et al.
Neurology|October 27, 2004
Clinical and neuropathologic variation in neuronal intermediate filament inclusion diseaseN J Cairns, M Grossman, S E Arnold, et al.
The New England Journal of Medicine|September 21, 2022
Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy M Miller, Merit E Cudkowicz, Angela Genge, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Nature Neuroscience|January 10, 2018
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTDChing-Chieh Chou, Yi Zhang, Mfon E Umoh, et al.
Neurobiology of Aging|April 23, 2010
Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosisElke Bogaert, An Goris, Philip Van Damme, et al.
Molecular Neurodegeneration|May 15, 2025
Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisAdam N Trautwig, Edward J Fox, Eric B Dammer, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Pageof 67